Professional Documents
Culture Documents
270112
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
4. Relacionar:
A. Cefotaxima 1. Primera generacin
B. Cefalexina 2. Segunda generacin
C. Ceftobiprole 3. Tercera generacin
D. Cefuroxima 4. Cuarta generacin
E. Cefepime
5. Quinta generacin
A) (A,1)(B,2)(C,3)(D,4)(E,5)
B) (A,3)(B,1)(C,5)(D,2)(E,4)
C) (A,5)(B,1)(C,3)(D,2)(E,4)
D) (A,2)(B,4)(C,5)(D,3)(E,1)
E) (A,5)(B,4)(C,3)(D,2)(E,1)
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
27. Uno de los siguientes antibiticos es til en infecciones por Staphylococcus aureus
Meticilino Resistente (MRSA) adquirido en comunidad:
A) Levofloxacino
B) Azitromicina
C) Clindamicina
D) Ciprofloxacino
E) Doxiciclina
28. Est indicado como monoterapia en las exacerbaciones agudas de la bronquitis
crnica:
A) Levofloxacino
B) Azitromicina
C) Moxifloxacino
D) Ciprofloxacino
E) Doxiciclina
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
29. Uno de los siguientes antibiticos acta a nivel de la SU 50S del ribosoma
bacteriano:
A) Cefalosporinas
B) Aminoglucsidos
C) Cloramfenicol
D) Tetraciclinas
E) Penicilinas
30. Cul de los siguientes antimicrobianos NO acta inhibiendo la sntesis de
protenas?:
A) Amikacina
B) Moxifloxacino
C) Doxiciclina
D) Azitromicina
E) Linezolid
31. Inhiben la sntesis de protenas a nivel del ribosoma bacteriano, excepto:
A) Gentamicina
B) Dalvabancina
C) Cloramfenicol
D) Doxiciclina
E) Azitromicina
32. Cul de los siguientes antimicrobianos NO acta inhibiendo la sntesis de
protenas?
A) Aminoglucsidos
B) Polimixina
C) Tetraciclinas
D) Macrlidos
E) Clindamicina
33. Cul de los siguientes antimicrobianos ejerce accin bactericida inhibiendo las
Topoisomerasas II y IV de las clulas bacterianas?
A) Amikacina
B) Teicoplamina
C) Doxiciclina
D) Ciprofloxacino
E) Clindamicina
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________